Benzinga

JULY 12, 2022

Pat Mulloy, President and Chief Executive Officer of Sharps, stated, "Sharps is a leading provider of comprehensive solutions for the small to medium generators of medical, hazardous and pharmaceutical waste. Raymond James & Associates, Inc. HOUSTON, July 12, 2022 (GLOBE NEWSWIRE) -- Sharps Compliance Corp.

Compliance 40

Compliance Private Equity Firm Equity Marketability 40

Cooley M&A

JANUARY 23, 2024

While the year saw an overall decline in M&A activity (down 17% from 2022) , total pharmaceuticals and life sciences deal value in 2023 increased by approximately 50% compared to 2022. Why did life sciences outperform the market? The last quarter of the year ended with a surge of deal activity.

Marketability 52

Marketability Equity Private Equity Firm Finance 52

Benzinga

OCTOBER 26, 2022

Sumitovant), in conjunction with parent company Sumitomo Pharma Co., billion on a fully diluted basis, and a total company value of $2.9 On October 23, 2022, Sumitovant Biopharma Ltd. per share in cash. per share in cash. This corresponds to a total transaction value of $1.7 billion on a fully diluted basis. BASEL, Switzerland, Oct.

Start-ups 40

Start-ups Marketability Technology 40

Musings on Markets

NOVEMBER 10, 2022

In my last post, I used Facebook's recent troubles to talk about the importance of corporate governance, and how we, as investors, have abandoned the power to change management at many younger tech companies in return for being able to invest in young tech companies, with growth potential and well-regarded founders.

Finance 74

Finance Start-ups Equity Equity Financing 74

Benzinga

AUGUST 4, 2022

NASDAQ: CLBS ) ("Caladrius" or the "Company"), a clinical-stage biopharmaceutical company developing innovative therapies designed to treat or reverse disease, today reported financial results for the three and six months ended June 30, 2022 and provided a business update. This is an exciting time for the Company and the future Lisata.

Start-ups 40

Start-ups Marketability Technology 40

Benzinga

MAY 16, 2022

NASDAQ: APRE ), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics targeting DNA damage response pathways today announced that it has acquired Atrin Pharmaceuticals Inc. Management and Organization. Cash and cash equivalents: As of March 31, 2022, the Company had $47.6

Equity 40

Equity 40

Benzinga

JUNE 26, 2023

June 26, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. NASDAQ: TNXP ) (Tonix Pharmaceuticals or Tonix) and its wholly-owned subsidiary Tonix Medicines, Inc. Chief Executive Officer of Tonix Pharmaceuticals. Chief Medical Officer of Tonix Pharmaceuticals. 7 ," said Seth Lederman, M.D.,

Marketability 40

Marketability Technology Finance 40